Enlicitide decanoate, a long-acting PCSK9 inhibitor designed for convenient dosing, demonstrated a favorable safety profile consistent with earlier studies, supporting its potential as a novel treatment option for patients with HeFH who require additional lipid lowering beyond standard therapies. https://www.coherentmarketinsights.com/news/mercks-enlicitide-decanoate-lowers-ldl-c-in-hefh-adults-1843